BTI-322 for induction therapy after renal transplantation: a randomized study.
Squifflet
J P
JP
Department of Renal and Pancreatic Transplantation, Cliniques UCL Saint-Luc, Brussels, Belgium.
Besse
T
T
Malaise
J
J
Mourad
M
M
Delcorde
C
C
Hope
J A
JA
Pirson
Y
Y
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D011239:Prednisolone / Q000627:therapeutic use; D015996:Survival Rate; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; C105249:LO-CD2a; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine